PRECISION BIOSCIENCES INC
DTIL · Biological Products, (No Diagnostic Substances) · 25.8M shares · -51%/yr ↓ buyback · EDGAR filings ↗
Reference price $3.84 · est. market cap ~$99M — last insider sale, 2026-02-18 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Early clinical-stage in vivo gene-editing company with encouraging Phase 1 HBV signals but no revenue base and deep losses.
Strengths
- Strong near-term liquidity (current ratio 13.3, 90th pct) and ARCUS platform differentiation
- PBGENE-HBV Phase 1 showed dose-dependent antiviral activity and no DLTs; PBGENE-DMD IND cleared
- Two lead programs advancing with partner-validated optionality (iECURE OTC)
Risks
- Revenue down 50% and earnings down 738% (1st pct); net margin -133%, going-concern-style burn
- Programs are still Phase 1 / preclinical — efficacy unproven and highly binary
- Nasdaq listing and substantial-additional-funding risks flagged in the filing
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -133.4%)
- Buying back stockNet buyback — share count -51%/yr over 3y
- Strong balance sheetStrong balance sheet — $116M cash & investments
- New fund positionNotable fund(s) opened this quarter: GOLDMAN SACHS GROUP INC
- Notable holderHeld by 4 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, STATE STREET CORP +1 more (as of 2026-03-31)
- Insider sellingInsider selling — 8 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, ~$431,271, last 6mo) Form 4 ↗
- Revenue declineRevenue -68.3% YoY
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-152.2%
Net margin
-133.4%
Return on equity
-49.6%
Return on assets
-29.6%
Revenue growth (QoQ)
-68.3%
Net-income growth
-738.0%
Current ratio
13.3×
EBITDA
-$51M
Tangible book value
$91M
Cash & investments
$116M
Stock comp / revenue
29.7%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-20 | Buehler Kevin | Option exercise | 21K | — |
| 2026-05-20 | Frankel Stanley | Option exercise | 21K | — |
| 2026-05-20 | Brown Melinda | Option exercise | 21K | — |
| 2026-05-20 | Pire Shari Lisa | Option exercise | 21K | — |
| 2026-05-20 | Germano Geno J | Option exercise | 21K | — |
| 2026-02-18 | SMITH J. JEFFERSON | Sell | 4.9K | $3.84 |
| 2026-02-18 | Amoroso Michael | Sell | 21K | $3.84 |
| 2026-02-18 | Kelly John Alexander | Sell | 8.1K | $3.84 |
| 2026-02-18 | Scimeca Dario | Sell | 4.9K | $3.84 |
| 2026-02-17 | Scimeca Dario | Option exercise | 17K | — |
| 2026-02-17 | Amoroso Michael | Option exercise | 68K | — |
| 2026-02-17 | Kelly John Alexander | Option exercise | 28K | — |
| 2026-02-17 | SMITH J. JEFFERSON | Option exercise | 17K | — |
| 2026-01-22 | Amoroso Michael | Sell | 35K | $4.17 |
| 2026-01-21 | Scimeca Dario | Sell | 8.9K | $4.03 |
| 2026-01-21 | Kelly John Alexander | Sell | 15K | $4.03 |
| 2026-01-21 | SMITH J. JEFFERSON | Option exercise | 16K | — |
| 2026-01-21 | SMITH J. JEFFERSON | Sell | 10K | $4.03 |
| 2026-01-20 | Scimeca Dario | Option exercise | 8.4K | — |
| 2026-01-20 | Scimeca Dario | Option exercise | 15K | — |
| 2026-01-20 | Kelly John Alexander | Option exercise | 3.9K | — |
| 2026-01-20 | Kelly John Alexander | Option exercise | 14K | — |
| 2026-01-20 | Kelly John Alexander | Option exercise | 27K | — |
| 2026-01-20 | SMITH J. JEFFERSON | Option exercise | 2.5K | — |
| 2026-01-20 | SMITH J. JEFFERSON | Option exercise | 10K | — |
| 2026-01-20 | Amoroso Michael | Option exercise | 37K | — |
| 2026-01-20 | Amoroso Michael | Option exercise | 69K | — |
| 2026-01-20 | Amoroso Michael | Option exercise | 8.9K | — |
| 2026-01-20 | Scimeca Dario | Option exercise | 2.0K | — |
| 2025-12-16 | Germano Geno J | Buy | 3.0K | $4.72 |
| 2025-12-16 | Frankel Stanley | Buy | 2.7K | $4.70 |
| 2025-12-15 | Brown Melinda | Buy | 1.4K | $4.97 |
| 2025-11-03 | Kelly John Alexander | Sell | 1.3K | $6.49 |
| 2025-11-03 | Scimeca Dario | Sell | 665 | $6.49 |
| 2025-11-03 | Amoroso Michael | Sell | 3.4K | $6.49 |
| 2025-11-02 | Kelly John Alexander | Option exercise | 3.6K | — |
| 2025-11-02 | Amoroso Michael | Option exercise | 9.4K | — |
| 2025-11-02 | Scimeca Dario | Option exercise | 1.8K | — |
| 2025-09-26 | Frankel Stanley | Buy | 2.7K | $4.97 |
| 2025-09-22 | Brown Melinda | Buy | 1.4K | $4.89 |
| 2025-07-03 | Kelly John Alexander | Sell | 15K | $4.26 |
| 2025-06-25 | Brown Melinda | Buy | 1.7K | $4.14 |
| 2025-06-25 | Buehler Kevin | Buy | 5.1K | $4.16 |
| 2025-05-27 | Germano Geno J | Option exercise | 9.8K | — |
| 2025-05-27 | Pire Shari Lisa | Option exercise | 9.8K | — |
| 2025-05-27 | Frankel Stanley | Option exercise | 9.8K | — |
| 2025-05-27 | Buehler Kevin | Option exercise | 9.8K | — |
| 2025-05-27 | Brown Melinda | Option exercise | 9.8K | — |
| 2025-03-26 | Brown Melinda | Buy | 1.8K | $4.75 |
| 2025-03-26 | Buehler Kevin | Buy | 4.5K | $4.67 |
| 2025-03-25 | Germano Geno J | Buy | 3.2K | $5.30 |
| 2025-03-24 | Amoroso Michael | Sell | 964 | $5.56 |
| 2025-03-21 | Amoroso Michael | Option exercise | 3.4K | — |
| 2025-03-04 | SMITH J. JEFFERSON | Sell | 154 | $4.91 |
| 2025-03-04 | Scimeca Dario | Sell | 272 | $4.91 |
| 2025-03-03 | SMITH J. JEFFERSON | Option exercise | 519 | — |
| 2025-03-03 | Kelly John Alexander | Option exercise | 1.7K | — |
| 2025-03-03 | Scimeca Dario | Option exercise | 919 | — |
| 2025-01-22 | SMITH J. JEFFERSON | Sell | 10K | $4.79 |
| 2025-01-22 | Scimeca Dario | Sell | 8.9K | $4.79 |
| 2025-01-21 | Amoroso Michael | Sell | 37K | $4.67 |
| 2025-01-20 | Scimeca Dario | Option exercise | 25K | — |
| 2025-01-20 | Amoroso Michael | Option exercise | 115K | — |
| 2025-01-20 | Kelly John Alexander | Option exercise | 44K | — |
| 2025-01-20 | SMITH J. JEFFERSON | Option exercise | 29K | — |
| 2024-12-30 | Germano Geno J | Buy | 3.6K | $4.49 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07254208 ↗ | A Long-term Observational Study in Participants Who Have Received PBGENE-HBV Chronic HBV Infection | — | Enrolling By Invitation | 2040-01-01 |
| NCT07429240 ↗ | PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | PHASE1/PHASE2 | Recruiting | 2029-11-01 |
| NCT06680232 ↗ | Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B HEPATITIS B CHRONIC | PHASE1 | Recruiting | 2025-12-01 |
| NCT04649112 ↗ | Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies CD19 Expressing Malignancies, Hematologic Malignancy | PHASE1 | Completed | 2022-12-22 |
| NCT04171843 ↗ | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma | PHASE1 | Terminated | 2022-10-19 |
| NCT04030195 ↗ | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | PHASE1/PHASE2 | Completed | 2021-06-24 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-16 | Material agreementDebt obligationExhibits | filing ↗ |
| 2026-05-27 | Reg FDOtherExhibits | filing ↗ |
| 2026-05-26 | Exec/director change5.03Shareholder voteExhibits | filing ↗ |
| 2026-05-05 | ResultsExhibits | filing ↗ |
| 2026-03-17 | Reg FDExhibits | filing ↗ |
| 2026-03-12 | ResultsExhibits | filing ↗ |
| 2026-02-11 | Reg FDOtherExhibits | filing ↗ |
| 2026-01-13 | ResultsReg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-16 | 2026-06-10 | 0001628280-26-043526 ↗ |
| 8-K | 2026-05-27 | 2026-05-27 | 0001628280-26-038307 ↗ |
| 8-K | 2026-05-26 | 2026-05-21 | 0001628280-26-038220 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001628280-26-030124 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0001628280-26-030123 ↗ |
| 8-K | 2026-03-17 | 2026-03-17 | 0001628280-26-018397 ↗ |
| 10-K | 2026-03-12 | 2025-12-31 | 0001628280-26-017019 ↗ |
| 8-K | 2026-03-12 | 2026-03-12 | 0001628280-26-017018 ↗ |
| 8-K | 2026-02-11 | 2026-02-11 | 0001628280-26-007114 ↗ |
| 8-K | 2026-01-13 | 2026-01-12 | 0001628280-26-001955 ↗ |
| 8-K | 2025-11-12 | 2025-11-10 | 0001628280-25-051382 ↗ |
| 8-K | 2025-11-10 | 2025-11-10 | 0001628280-25-051168 ↗ |